Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab

J Am Acad Dermatol. 2004 May;50(5 Suppl):S75-7. doi: 10.1016/j.jaad.2003.11.044.


Infliximab, a chimeric mouse-human monoclonal antibody, blocks the action of tumor necrosis factor-alpha and is a highly effective treatment for several inflammatory disorders, including inflammatory bowel disease and rheumatoid arthritis. Although safety data are encouraging, immunosuppressive sequelae may result. We report the acute development of multiple squamous cell carcinomas and keratoacanthomas in a patient receiving infliximab for rheumatoid arthritis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / immunology
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Carcinoma, Squamous Cell / etiology*
  • Carcinoma, Squamous Cell / immunology
  • Female
  • Humans
  • Infliximab
  • Keratoacanthoma / etiology*
  • Keratoacanthoma / immunology
  • Skin Neoplasms / etiology*
  • Skin Neoplasms / immunology


  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab